nadunolimab
cantargia
['nadunolimab', 'pancreatic', 'cantargia']
cantargia: new efficay data on nadunolimab + gem/abraxane in 73 patients with pancreatic cancer. the data, showing durable responses and median survival of 12.7 months, received lots of positive attention today at asco. really motivating for upcoming steps! 
Computers are useless. They can only give you answers.